Tumor is able to bear or endure property of a medicine is to show tumor cell defies tumor medicaments expression is irresponsive condition, it is the central segment that ovarian cancer changes cure to fail.

On cellular level, but will be able to bear or endure cent of property of a medicine is inherent be able to bear or endure property of a medicine and acquired character are able to bear or endure property of a medicine two kinds. Acquired character is able to bear or endure property of a medicine is ovarian cancer is able to bear or endure main reason of medicine.

Change cure with what alexipharmic access is a foundation

1. Be able to bear or endure medical mechanism

In the most and malignant tumor such as ovarian cancer, s of peptide of cereal Guang pleasant transfers enzymatic expression to increase. A lot of fighting tumor medicaments basically passes generation active oxygen to had reached oxidation fat to kill and wound tumor cell character inside body, and move of S of peptide of cereal Guang pleasant is enzymatic can keep clear of these active oxygen had been mixed oxidation fat is qualitative, the interference medicaments destruction to tumor cell action, bring about tumor cell to be able to bear or endure thereby medicine.

2. Represent medicaments

Telcyta is one kind counts this way fight tumor medicaments, its splitting decomposition child can change enzymatic incorporation with S of peptide of cereal Guang pleasant, restrain tumor cell to be able to bear or endure medicine, also can produce reaction with the DNA of tumor cell, RNA and protein, kill and wound tumor cell.

This medicine did not kill and wound action to normal cell, poisonous side effect is little.

Original, the associated application Telcyta such as Telik and platinum kind cure is able to bear or endure property of a medicine is ovarian cancer, 68% patients are obtained alleviate. Clinical trial shows a much center that having, treatment of Telcyta only drug can make 50% patients patient's condition stable, of small dose group and patient of cure of high dose Telcyta alleviate rate it is respectively 15% with 19% . Multinomial Ⅱ period clinical trial considers to show, telcyta alone or the curative effect that uses those who treat ovarian cancer jointly with other remedy is distinct, at present this medicine already entered Ⅲ period clinical trial phase.

Die with wither access is a foundation change cure

1. Be able to bear or endure medical mechanism

The AKT in airframe of ovarian cancer patient can activation with a series of exciting elements PI3K/AKT axis and access of NF- κ B, restrain cellular wither to die, reduce the curative effect of the medicaments that change cure.

2. Represent medicaments

17-AAG is a kind of representative buildup cellular wither dies fight tumor medicaments, it can promote folding of mistake of degradation of protein enzymatic substance to heat up shock albumen (Hsp)90, then restrains a cell to grow, revulsive cell wither dies, play combats tumor effect.

PS341 is another kind is based on this access fight tumor medicaments, can the active that reversibility controls albumen enzymatic aspect, affect the activation of NF- κ B, jie fights Bcl-2 to fight cellular wither revulsively to die effect, thereby wither of revulsive tumour cell dies, generation combats tumor effect.

Current, as have the new drug that fights tumor action distinctly, in the clinical trial that 17-AAG and PS341 are being used at a variety of blood systems and hypostatic tumour cure.

With growing factor and signal turn guide access is a foundation change cure

1. Action mechanism

Use skin to grow the analogue of factor, grow with skin factor suffers body to be target dot, play fights tumor action.

2. Represent medicaments

Ji Fei replaces the Buddhist nun and Erlotinib all is FDA approval appears on the market this kinds fight tumor new drug, they alone or combine with other remedy, usable Yu Bo kind or yew is mellow kind etc be able to bear or endure the cure of ovarian cancer of medicine, already entered Ⅱ period clinical trial, but the only drug of two medicine uses curative effect all not beautiful.

Sensitivity of the medicaments that change cure and be able to bear or endure analysis sufferring a gender

1. Experimental method

Put forward applicable to change cure medicaments with all possible means in the world now sensitivity and be able to bear or endure experiment of analysis sufferring a gender will coach be able to bear or endure property of a medicine is ovarian cancerous cure. This method basically is the tumor cell of patient of detached and ovarian cancer, brood jointly with the medicaments that change cure outside body Yo, obtain the information that gathers individual tumour cell to react to all sorts of medicaments that change cure, choose sensitive medicaments to have treatment thereby.

2. Clinical experiment

The ovarian to 371 cancer such as Gallion and peritoneal cancer patient undertook sensitivity is mixed changing cure medicaments be able to bear or endure experiment of analysis sufferring a gender. The basis checks a result, divide the patient 3 groups and give sensitivity respectively medicaments, medium degree of sensitivity medicaments and be able to bear or endure medicaments sufferring a gender has treatment, final 135 patients were accepted monitor and follow visit.

The result shows, in the progress risk respect of tumor, sensitivity medications group, medium spend sensitivity to medication group and be able to bear or endure suffer a gender to medication the group is ordinal and elevatory, and of tumor do not have progress period ordinal shorten. Investigator thinks, sensitivity of the medicaments that change cure and be able to bear or endure analysis sufferring a gender is usable at progress of tumour of ovarian cancer patient the time limit of interval period is forecasted, also be clinical and reasonable provide beneficial guidance with medicine, improvement is able to bear or endure property of a medicine is ovarian remedial effect of cancer.

3. The advantage reachs inadequacy

Aghajanian of center of cancer of American souvenir Sloan-Kettering think, the choice using drug that to be able to bear or endure ovarian cancer treats property of a medicine, the be fond of that the experience according to the doctor is a patient even basically is on the tradition, use this to analyse a method to be able to stop this kind of blind action reasonably, reduce noxiousness reaction, defer illness progress and medicaments of cure of firm second line, make the patient achieves better curative effect thereby. Accordingly, sensitivity of the medicaments that change cure and be able to bear or endure analysis sufferring a gender, can consider to regard as clinical the convention that attend detects index.

Of course, method of this kind of analysis had be notted standardize, if did not make clear former hair between kitchen and organization of move kitchen tumour, without changing the analysis between cure and organization of the tumour after changing cure as a result He Yi is the same as; clinical doctor is subjective on the patient draw materials with large volume of apt choice tumour undertakes an analysis, its are prognostic and corresponding poorer also, but the conclusion that reachs accordingly still is not pushed reach in be not this kinds of patient.

Anyhow, above medicaments and method give be able to bear or endure the cure of ovarian cancer brought property of a medicine new hope, believe to apply as what await the emerge in large numbers that chooses medicaments and new method newly, be able to bear or endure the remedial foreground of ovarian cancer meets property of a medicine more bright.

　 Small make up recommend: What treatment does ovarian cancer have? [The detail looks please >> >>Ovarian tumour treats an encyclopedia]